iCAD-full-color.jpg
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
March 19, 2024 09:00 ET | iCAD, Inc.
NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD-full-color.jpg
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
March 12, 2024 16:01 ET | iCAD, Inc.
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H.,...
iCAD-full-color.jpg
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
February 28, 2024 08:05 ET | iCAD, Inc.
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially...
iCAD-full-color.jpg
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
February 27, 2024 09:05 ET | iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably...
iCAD-full-color.jpg
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
February 27, 2024 08:05 ET | iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD-full-color.jpg
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 06, 2024 08:00 ET | iCAD, Inc.
NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD-full-color.jpg
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
January 30, 2024 08:00 ET | iCAD, Inc.
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD-full-color.jpg
iCAD Expands Executive Sales Leadership Team as Business Grows
December 18, 2023 08:00 ET | iCAD, Inc.
NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales...
iCAD-full-color.jpg
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
November 28, 2023 08:00 ET | iCAD, Inc.
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized...
iCAD-full-color.jpg
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
November 27, 2023 08:00 ET | iCAD, Inc.
New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast...